And I predict that 2025 will be another momentous year for Summit. Summit already owned the license to market ivonescimab in ...

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 01/27/2025. Discounted offers are only available to new ...